Literature DB >> 18259988

Structure-function analyses of single nucleotide polymorphisms in human N-acetyltransferase 1.

Jason M Walraven1, John O Trent, David W Hein.   

Abstract

Human N-acetyltransferase 1 (NAT1) alleles are characterized by one or more single nucleotide polymorphisms (SNPs) associated with rapid and slow acetylation phenotypes. NAT1 both activates and deactivates arylamine drugs and carcinogens, and NAT1 polymorphisms are associated with increased frequencies of many cancers and birth defects. The recently resolved human NAT1 crystal structure was used to evaluate SNPs resulting in the protein substitutions R64W, V149I, R187Q, M205V, S214A, D251V, E261K, and I263V. The analysis enhances knowledge of NAT1 structure-function relationships, important for understanding associations of NAT1 SNPs with genetic predisposition to cancer, birth defects, and other diseases.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18259988      PMCID: PMC2265210          DOI: 10.1080/03602530701852917

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  54 in total

1.  Structure of arylamine N-acetyltransferase reveals a catalytic triad.

Authors:  J C Sinclair; J Sandy; R Delgoda; E Sim; M E Noble
Journal:  Nat Struct Biol       Date:  2000-07

2.  Characterization of naturally occurring and recombinant human N-acetyltransferase variants encoded by NAT1.

Authors:  J H de León; K P Vatsis; W W Weber
Journal:  Mol Pharmacol       Date:  2000-08       Impact factor: 4.436

3.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

4.  Eubacterial arylamine N-acetyltransferases - identification and comparison of 18 members of the protein family with conserved active site cysteine, histidine and aspartate residues.

Authors:  Mark Payton; Adeel Mushtaq; Tin-Wein Yu; Ling-Juan Wu; John Sinclair; Edith Sim
Journal:  Microbiology (Reading)       Date:  2001-05       Impact factor: 2.777

5.  Correlation between genotype and phenotype of the human arylamine N-acetyltransferase type 1 (NAT1).

Authors:  C Bruhn; J Brockmöller; I Cascorbi; I Roots; H H Borchert
Journal:  Biochem Pharmacol       Date:  1999-12-01       Impact factor: 5.858

6.  Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2.

Authors:  G H Goodfellow; J M Dupret; D M Grant
Journal:  Biochem J       Date:  2000-05-15       Impact factor: 3.857

7.  Relevance of N-acetyltransferase 1 and 2 (NAT1, NAT2) genetic polymorphisms in non-small cell lung cancer susceptibility.

Authors:  H Wikman; S Thiel; B Jäger; P Schmezer; B Spiegelhalder; L Edler; H Dienemann; K Kayser; V Schulz; P Drings; H Bartsch; A Risch
Journal:  Pharmacogenetics       Date:  2001-03

8.  Functional characterization of nucleotide polymorphisms in the coding region of N-acetyltransferase 1.

Authors:  A J Fretland; M A Doll; M A Leff; D W Hein
Journal:  Pharmacogenetics       Date:  2001-08

9.  Maternal smoking and the risk of orofacial clefts: Susceptibility with NAT1 and NAT2 polymorphisms.

Authors:  Edward J Lammer; Gary M Shaw; David M Iovannisci; Janee Van Waes; Richard H Finnell
Journal:  Epidemiology       Date:  2004-03       Impact factor: 4.822

10.  Proteasomal degradation of N-acetyltransferase 1 is prevented by acetylation of the active site cysteine: a mechanism for the slow acetylator phenotype and substrate-dependent down-regulation.

Authors:  Neville J Butcher; Ajanthy Arulpragasam; Rodney F Minchin
Journal:  J Biol Chem       Date:  2004-03-23       Impact factor: 5.157

View more
  10 in total

1.  Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

Review 2.  Arylamine N-acetyltransferases: a structural perspective.

Authors:  Xiaotong Zhou; Zhiguo Ma; Dong Dong; Baojian Wu
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

3.  Functional effects of genetic polymorphisms in the N-acetyltransferase 1 coding and 3' untranslated regions.

Authors:  Yuanqi Zhu; J Christopher States; Yang Wang; David W Hein
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2011-02-02

4.  Identification and characterization of potent, selective, and efficacious inhibitors of human arylamine N-acetyltransferase 1.

Authors:  Carmine S Leggett; Mark A Doll; Raúl A Salazar-González; Mariam R Habil; John O Trent; David W Hein
Journal:  Arch Toxicol       Date:  2021-11-16       Impact factor: 5.153

5.  Mesalazine pharmacokinetics and NAT2 phenotype.

Authors:  Hendrik Lück; Martina Kinzig; Alexander Jetter; Uwe Fuhr; Fritz Sörgel
Journal:  Eur J Clin Pharmacol       Date:  2008-08-14       Impact factor: 2.953

Review 6.  N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.

Authors:  David W Hein
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

7.  Human disposition, metabolism and excretion of etamicastat, a reversible, peripherally selective dopamine β-hydroxylase inhibitor.

Authors:  Ana I Loureiro; Jose F Rocha; Carlos Fernandes-Lopes; Teresa Nunes; Lyndon C Wright; Luis Almeida; Patricio Soares-da-Silva
Journal:  Br J Clin Pharmacol       Date:  2014-06       Impact factor: 4.335

8.  Safety, tolerability, and pharmacokinetics of etamicastat, a novel dopamine-β-hydroxylase inhibitor, in a rising multiple-dose study in young healthy subjects.

Authors:  Teresa Nunes; José F Rocha; Manuel Vaz-da-Silva; Bruno Igreja; Lyndon C Wright; Amílcar Falcão; Luis Almeida; Patricio Soares-da-Silva
Journal:  Drugs R D       Date:  2010

9.  FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects.

Authors:  David Lagorce; Olivier Sperandio; Hervé Galons; Maria A Miteva; Bruno O Villoutreix
Journal:  BMC Bioinformatics       Date:  2008-09-24       Impact factor: 3.169

Review 10.  Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery.

Authors:  E Sim; A Abuhammad; A Ryan
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.